Five Codes Left the Zero List This Morning

Commerce filed seven pages of housekeeping at 4:15 on Monday afternoon. It published this morning.

Most of it is definitions. What counts as a nuclear medicine, what counts as a plasma derived therapy, which nineteen jurisdictions can claim the specialty zero rate, and where to email if your product meets an urgent US health need.

Submissions open today.

The part that moves money is one paragraph in section V.

"Which tariff lines did the correction actually move, and how much trade is standing on them?"

What Came Off the List

Proclamation 11020 runs on two enumerated lists.

Subdivision (c) of U.S. note 40 names the HTSUS provisions the section 232 pharmaceutical action reaches. Annex IV names provisions it does not reach, at a rate of zero.

Five codes were on both lists. The notice takes them out of the zero one:

"The technical correction to Annex IV corrects an inconsistency of certain HTSUS Classifications listed in Annex IV that overlap with Annex I. The following HTSUS codes are removed from Annex IV: 2937.23.50, 3002.13.00, 3002.14.00, 3002.15.00, and 3004.49.00."

Four of those five are the only eight-digit breakout under their six-digit subheading, so trade data sizes them exactly. Together they carried $92.8 billion of US imports in 2025, and 85 percent of that sits in one code (chart below).

3002.15.00 is "Immunological products, put up in measured doses or in forms or packings for retail sale." Its first ten-digit child is "Containing monoclonal antibodies."

$78.7 billion arrived on it last year.

The fifth code, 2937.23.50, is estrogens and progestins, other. It sits under a heading that took $75.4 million all in, so it is rounding here, and its bar is the parent total.

Now, the obvious caveat, stated before anyone else states it for us. That $92.8 billion is the size of the customs lines.

The duty reaches patented pharmaceutical articles, generics are outside the scope at this time, and the rate that actually lands depends on origin.

Ninety Percent of It Pays Fifteen

Origin decides nearly everything on this line.

Of the $78.7 billion that arrived under 3002.15.00 last year, $70.8 billion came from the European Union, Japan, South Korea or Switzerland. That is 90.0 percent of the line.

Ireland alone was $19.2 billion and Germany $17.9 billion.

Those origins have their own heading, 9903.04.62, at 15 percent. The United Kingdom, another 1.1 percent, went to zero back on July 31.

So the exposure this correction confirms is mostly a fifteen-point line.

The rest is where the 100 percent lands: $7.0 billion, 8.9 percent of the code, and $5.7 billion of that is Singapore. If your dosed biologic ships out of Singapore rather than Shannon, September 29 is a different morning for you than it is for the buyer down the hall.

They Corrected Five and Left Four

Here's the catch.

The notice reprints both corrected lists in full, which is the first time either has been readable outside the April annexes PDF. We counted them again.

Note 40(c) now names 149 ten-digit codes, up from the 131 the desk counted on September 19. Annex IV now names 521, down from 526.

And four ten-digit codes still appear on both lists as published: 3004.90.9212, 3004.90.9217, 3004.90.9218 and 3004.90.9226. The second of those is the line for medicaments containing tacrolimus or mycophenolate mofetil, which is to say the transplant immunosuppressants.

CBP published the tie-break in July: "If a product is subject to more than one rate of duty under the Proclamation, then the lowest applicable rate shall apply."

Lowest here means zero. Worth knowing which of your own codes that sentence is quietly doing the work for.

One more line in the same annex earns a look if you import for development work. New heading 9903.04.70, at zero, covers articles "solely for use in clinical trials, research and development, or other non-commercial applications."

Material for a trial and material for a launch now enter under different chapter 99 headings.

Final Thoughts

A proclamation is the announcement. The annexes are the instrument, and the instrument keeps moving: the UK rate went to zero on July 31, and five codes came off the zero list at 4:15 on Monday afternoon.

Six days is not much time to re-run a classification review. It is enough time to check five codes, and to notice that the list your broker is working from was superseded this morning.

Thanks for reading.